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ABSTRACT 
Acute head trauma is often a clinical challenge in diagnosing the brain damage, 
assessing its severity and prognosis, and establishing the optimal treatment. 
Different patients, with brain damage of apparent comparable severity according to 
the imaging examination, may have different neurological evolution or different 
response to therapy. 
Minor traumatic brain injuries can induce a brief loss of consciousness or confusion, 
are usually benign, but sometimes they cause persistent and progressive brain 
symptoms in the long run. However, at present, there are no reliable methods that 
can diagnose properly minor traumatic brain injuries. 
Biomarkers of the brain injuries allow the monitoring of both physiological and 
pathological processes. The identification of such biomarkers could allow a better 
understanding of the pathological processes involved in traumatic brain injuries, 
their diagnosis, prognosis and may facilitate the establishment of a better treatment 
regimen for these patients. 
In this article, the authors make a brief review of the literature in which they analyse 
the biomarkers of the lesions of the various brain structures identified so far, which 
can be detected in biological fluids (blood, cerebrospinal fluid) and the advantages 
and limitations of their use in the current medical practice. 
 
 
INTRODUCTION  
Brain injury may be graded by Glasgow Coma Scale score (GCS) in: 
severe trauma, characterized by a GCS score of less than or equal to 8- 
the cerebral coma equivalent; moderate trauma, characterized by a 
GCS score of 9-12 [1], of which 10% of patients will experience 
neurological deterioration and cerebral coma and minor trauma, 
where the GCS score is between 13 and 15 [2]. 
 Minor brain trauma can be characterized by the loss of 
consciousness of short duration- up to 30 minutes, or confusion, 
retrograde amnesia to the traumatic event of up to 24 hours, headache,
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vomiting (unrelated to intracranial hypertension) 
and/ or transient focal neurological signs or 
convulsions [1]. Most patients with minor brain 
trauma show favourable progression, but about 3% 
of cases have an unfavourable progression, with 
increased risk for intracranial haemorrhage and 
diffuse axonal injuries, the promoters of cognitive, 
motor and psychosocial deficits [2]. The morbidity 
associated with cerebral traumatic injuries (even 
minor) is considerable. Studies have shown that 
between 1 and 20% of patients with minor traumatic 
brain injuries develop persistent physical, cognitive 
and behavioural disorders [3], such as chronic 
dizziness, fatigue, headache, and amnesia. It is also 
important that in the clinic, minor brain injuries are 
more common than stroke, dementia and epilepsy, 
indicating their high prevalence and justifying the 
efforts to diagnose and treat them as accurately as 
possible. 
Despite substantial efforts to clarify and improve 
the diagnostic criteria for minor traumatic brain 
injuries, compared to moderate and severe brain 
injuries, the former often remain a diagnostic 
challenge. This is largely due to the rapid resolution 
of acute signs and symptoms after a simple rest and 
the absence, in many cases, of objective 
neuroimaging evidence. 
Current diagnosis regimens for minor traumatic 
brain injuries often face the difficulty of 
differentiating them from non-traumatic pathologies 
that may exhibit a similar symptomatology. 
Currently, the gold standard for diagnosing and 
establishing the therapeutic management of 
traumatic brain injuries is the computer tomography 
(CT) exam. It allows the detection of various 
traumatic head injuries, such as cranial fractures, 
extra- and subdural hematomas, subarachnoid 
haemorrhage, cerebral contusion and laceration, 
cerebral edema, etc. With increased sensitivity and 
specificity and by using it in the clinic as a routine 
exam, the head CT scan surpassed the simple head 
radiography [1]. However, the head radiography 
retains its importance in the initial classification of 
traumatic brain injuries as complicated injuries 
(radiographically proven) or uncomplicated injuries 
(negative radiography), and thus contributes to 
establishing the necessary further investigations, 
such as CT scan or MRI, and the therapeutic 
management (hospital admission with or without 
surgery). Despite the superior results from classical 
X-rays, modern imaging modalities such as CT scan 
and MRI are costly and entail a number of risks, 
including the risk of irradiation and the risk 
associated with the administration of the contrast 
substance [3]. Also, in many cases, minor traumatic 
brain injuries cannot be detected by CT scan. Under 
these circumstances, an additional diagnostic tool is 
necessary to detect patients at risk of developing 
further complications. 
 
BIOMARKERS OF CEREBRAL LESIONS - 
PATHOPHYSIOLOGICAL BACKGROUND  
Research on biomarkers of neuronal lesions began 
after the 1950s, and their interest has increased 
significantly over the past 25 years.  
Biomarkers, also called biological markers, are 
natural characteristics that can be measured and 
interpreted objectively as indicators of biological 
processes or responses to therapeutic interventions 
[4]. Biomarkers are indicators of physiological, 
pathological or pharmacological processes. Each 
organ system has more or less specific biomarkers, 
and their analysis, either isolated or joined to other 
clinical investigations, allows monitoring of an 
individual's health status [2].  
 From the pathophysiological point of view, due to 
the brain injuries, the neuronal and astroglial 
network loses its structural integrity, cellular 
membranes are affected and secondary to these 
events, biomarkers are released in the cerebrospinal 
fluid and in blood, allowing for the diagnosis and 
prognosis of brain injuries [5].  
 Traumatic mechanical forces can determine cell 
damage due to shear, rupture and stretching of 
neurons, axons, glial cells and blood vessels, and the 
lesion will induce biochemical changes such as 
excitotoxicity, necrosis and apoptosis, oxidative 
stress and inflammation.   Similar pathophysiological 
changes can also be seen in disorders induced by 
acute pathological brain injury such as stroke.  
 Sensitive and specific biomarkers that reflect the 
brain damage can provide important information 
about the pathophysiology of traumatic brain 
injuries and can predict abnormal CT results and/ or 
the development of residual deficits in patients 
suffering from minor traumatic brain injuries. 
Biomarkers could be diagnostic criteria for traumatic 
brain injuries and could be a valuable adjuvant to 
clinical and routine imaging. In particular, the 
possibility of using biomarkers in patients with minor 
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traumatic brain injuries could provide a rapid, 
differential, non-invasive and cost-effective 
diagnostic test to guide appropriate patients’ triage 
and their early management [6]. 
 
BIOMARKERS OF BRAIN INJURIES –  
PROMISING RESULTS 
A wide range of proteins, of different origins and 
resulting from various pathways, have been studied 
as biomarkers for diagnosis and prognosis of brain 
injuries. However, the performance of many of 
these biomarkers has not been studied in the case 
of minor traumatic brain injuries [7]. 
At the level of the central nervous system, the 
lesion biomarkers studied to date are S100beta, Glial 
Fibrillary Acidic Protein (GFAP), Neuron- Specific 
Enolase (NSE), Alpha II Spectrin, Tau protein, 
Ubiquitin C-Terminal Hydrolase L1 (UCH-L1), Fatty-
Acid-Binding Proteins (B-FABP, H-FABP) and Il-10. 
 Among the listed biomarkers, the most studied 
are S100 beta and Neuron- Specific Enolase (NSE), 
the values of which increase in hypoxic conditions, 
starting on the 2nd post-traumatic day and 
normalize at about 4 days after the trauma [2]. 
 S100 beta is a dimer that binds cell calcium, is 
involved in cellular differentiation and neuronal 
proliferation and has a life span of about 2 hours. 
There are 19 types of such dimers, of which S100A1 
(in skeletal muscles, heart, and kidneys), S100A1B (in 
astrocytes), S100B (in astrocytes and Schwan cells) 
and S100BB (in astrocytes). The low molecular 
weight of 21kDa allows the S100beta dimers to easily 
cross the blood-brain barrier, so that in brain injuries 
high levels of S100beta are found in the blood. Unlike 
the NSE, the plasma level of S100beta is not affected 
by hemolysis, 21.2 micrograms/ liter suggesting the 
installation of anoxic coma, and 15.2 micrograms/ 
liter indicates neuronal recovery.  
 Neuron- Specific Enolase (NSE) is an isoform dimer 
involved in glucose metabolism, which is normally 
not found in the peripheral blood. In patients with 
stroke, the NSE value increases, with higher values 
for patients with irrecoverable traumatic brain 
injuries compared to patients with favourable 
progression. Decreasing NSE values at 24-48 hours 
after the trauma usually indicates a good prognosis, 
while a value greater than or equal to 30 
micrograms/ liter, 48 hours post-trauma, predicted 
death in 100% of the cases. As mentioned above, NSE 
values are influenced by hemolysis, which does not 
allow its determination in peripheral blood. Apart 
from brain lesions, other sources of NSE may also be 
small cell carcinomas, neuroblastoma, 
haemorrhagic shock, femoral fracture, ischemia and 
local reperfusion. 
 Glial Fibrillary Acidic Protein (GFAP) is a monomer, 
being an intermediate protein derived from 
astroglial cells. GFAP has increased specificity for 
neuronal tissue, with high values in degenerative 
brain diseases, cerebral infarction, severe brain 
injury, and axonal injuries. GFAP is a predictive 
indicator for the recovery of anoxic cerebral coma, 
but studies conducted so far on this monomer are 
contradictory, and further research is needed on 
post-mortem biological products. 
 Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) is a 
compound that plays a role in the elimination of 
oxidized neuronal proteins under both normal and 
pathological conditions. Initially, it was used as a 
histological marker for neurons. Recently, UCH-L1 
has been found to have elevated values in the 
cerebrospinal fluid after a traumatic brain injury, 
which can be immediately detected post-
traumatically, with elevated values lasting for about 
one week [2]. 
 Both S100B and the combination of GFAP and 
UCH-L1 were promising in screening for CT 
positivity/ negativity among patients with acute 
traumatic brain injury [8]. 
 Alpha II Spectrin is a major component of the 
cortical membrane of the cytoskeleton, being 
present in axons and presynaptic terminations. It is 
a marker for apoptosis and necrosis in the post-
traumatic initial stages and has high values in 
moderate and severe brain injuries [2]. 
 Tau is a microtubule associated protein, which is 
necessary to maintain the structural integrity of the 
axons. Tau proteins have also other functions, such 
as nerve impulse transmission, synaptic activity, 
cellular proliferation, neurobiological development 
and neuroplasticity. Phosphorylation of Tau proteins 
is a normal metabolic process, while in both aging 
and neurodegenerative diseases, Tau proteins 
undergo hyper-phosphorylation, which determines 
their aggregation as fibrillar deposits. Post mortem 
studies on human corpses described different 
patterns of taunting, depending on the pathological 
phenotype. Recent studies also highlight the 
uniqueness of pathological models, including a 
model attributed to repetitive cerebral trauma, 
 113 Biomarkers of the brain injuries - the future diagnosis standard in head trauma? 
although clinical correlations were relative [9]. 
 Fatty-Acid-Binding Proteins (FABPs) are non-
enzymatic cytoplasmic proteins involved in 
intracellular buffering and transport of fatty acids. 
These are 9 distinct protein types, each named after 
the tissue in which it was first detected. FABPs are 
rapidly released into circulation from the injured 
cells and are eliminated by the kidney, with a half-life 
of about 20 minutes. B-FABP was first identified in 
the rodent brain where it has a variable 
concentration depending on the animal’s age (stage 
of development). Thus, in adult mice, B-FABP is 
usually produced at low concentrations and is 
detected only in glial cells of the white matter. Unlike 
B-FABP, H-FABP is also detected in neurons of the 
gray matter. B-FABP and H-FABP proteins have 
different brain tissue distribution, with the highest 
concentrations in the frontal lobe. However, in all 
brain structures it was observed that the level of H-
FABP concentration is about 10 times higher than the 
B-FABP concentration. Studies show that these two 
proteins have greater susceptibility to minor 
cerebral lesions than the currently used markers, 
S100B and NSE respectively [10].  
 
DIAGNOSTIC RELEVANCE OF BIOMARKERS OF CEREBRAL 
INJURIES 
To date, biomarkers of cerebral injuries have been 
detected in cerebrospinal fluid and in peripheral 
blood. It has been found that in cases where the 
blood-brain barrier is intact, cerebral proteins are 
only present in small amounts in blood. The 
condition of the blood-brain barrier has, therefore, 
an important influence on the concentration of those 
proteins in the blood, which should be considered 
for the interpretation of the cerebral lesion-specific 
biomarkers [7]. 
 The cerebrospinal fluid is in direct contact with 
the extracellular matrix of the brain, and its 
composition reflects the biochemical changes 
occurring in this organ. For these reasons, the 
cerebrospinal fluid could be an optimal source of 
brain damage biomarkers. Several cerebral lesion- 
specific biomarkers have already been described, 
including proteins that indicate the integrity of the 
blood-brain barrier and neuro-inflammation, as well 
as axonal, neuronal and astrogial lesions. Some 
proteins that are expressed in the central nervous 
system are also detectable in peripheral blood, albeit 
at very low concentrations due to their dilution in the 
much larger volume of the extracellular plasma and 
matrix of peripheral tissues. Because peripheral 
blood sampling is much easier in practice than the 
collection of the cerebrospinal fluid, a series of 
cerebrospinal fluid biomarkers specific for minor 
traumatic brain injuries have also been evaluated in 
the peripheral blood. The low concentration of 
potential biomarkers in the peripheral blood is, 
however, a technical limitation on the use of most 
standard immunological tests. However, the number 
of potential biomarkers of cerebral lesions in the 
peripheral blood studied is steadily increasing as the 
analytical tools for detecting them become more and 
more sensitive [11].  
 Studies have shown that unique biomarkers do 
not have the specificity and sensitivity required for 
their use as diagnostic tools. For a biomarker to be 
useful its sensitivity and specificity should be very 
high to ensure diagnosis and prognosis assessment 
without the need for a CT brain exam. 
 So far, most research on biomarkers of minor 
traumatic brain injuries has been performed with 
unique biomarkers. The combination of different 
biomarkers has been suggested to enhance the 
diagnostic performance. Several studies have shown 
that combinations of biomarkers significantly 
increase diagnostic performance in various 
pathologies, such as sleep disorders, post-stroke 
subarachnoid haemorrhage, lung cancer or 
differentiation of post-traumatic brain injuries from 
other types of lesions. Furthermore, it has been 
suggested that some combinations of different 
clinical parameters, such as the age and types of 
biomarkers, e.g. inflammatory proteins, can improve 
the classification of lesions [7]. 
 In a multicentre study, 13 cerebral biomarkers, all 
previously investigated in patients with stroke, were 
evaluated for their ability to correctly classify patients 
with minor traumatic brain injury, CT positive and CT 
negative, with a GCS score of 15 and showing at least 
one clinical symptom. Of the 13 biomarkers, the H-
FABP and IL 10 proteins were the best single 
markers. These were further compared and 
combined with the better-studied S100B and GFAP 
markers. H-FABP was the best single marker, but 
when combined with GFAP, the overall performance 
increased from 32% to 46%, with a sensitivity of 
100%. Proteins have been shown to be released 
from various types of injured cells. S100B and GFAP 
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were derived from astrocytic lesions, H-FABP from 
endothelial cells and neuronal cellular bodies, while 
IL10 is expressed by monocytes and macrophages 
[7]. 
 Detection of cerebral lesions by the serum 
biomarkers is not a standard procedure in current 
clinical practice, although several proteins, such as 
S100B, NSE, myelin basic protein and GFAP show 
promising results [10]. Some biomarkers, such as 
S100B and GFAP, have been extensively studied in 
the blood of patients with minor traumatic brain 
injuries, but so far none seem to provide sufficient 
information [7]. 
 
DIFFICULTIES AND LIMITATIONS IN THE STUDY OF 
BIOMARKERS OF BRAIN INJURIES 
The main difficulty facing biomarkers for brain 
damage is to know whether the measured proteins 
really come from the brain injuries. As shown above, 
regardless of their origin, single biomarkers do not 
have sufficient performance to be transformed into 
diagnostic tools. Biomarker combinations, however, 
have been shown to enhance diagnostic 
performance when proteins of different origins and 
pathways are combined, due to the complexity of the 
nervous system and the heterogeneity of the 
traumatic brain injuries [7, 8].  
 There are also other obstacles to the 
development of a series of blood biomarkers for 
minor traumatic brain injuries. The blood-brain 
barrier prevents the evaluation of the biochemical 
changes in the brain by using biomarkers in the 
blood, but this is possible, however, in the case of 
loss of blood-brain barrier integrity, which occurs in 
severe brain lesions. In addition, some potential 
biomarkers suffer a proteolytic degradation in the 
blood, and their levels may be affected by clearance 
in the blood through the liver or kidneys. The 
accuracy of immunoassays may also be affected by 
the binding of biomarkers to carrier proteins and 
extra-cerebral sources of biomarkers [12]. 
 Biomarkers of the cerebral injuries have different 
delivery patterns, and this has limitations on their 
practical use. As a result, clinical applicability may be 
limited by the type of brain injury (traumatic, stroke, 
hypoxia-ischemia). Another important limitation in 
the analysis of cerebral biomarkers is their ambiguity 
in multiple lesions. 
Despite the current limitations in the study and 
application of biomarkers of cerebral lesions in the 
current medical practice, biomarkers could be used 
in the future as an adjuvant, supplementing the 
traditional and neuro-imaging examination in the 
diagnosis and prognosis of patients with traumatic 
brain injuries [4]. 
 
CONCLUSIONS 
Traumatic brain injuries may raise clinical challenges 
due to the diagnostic difficulties and the lack of 
specific prognostic tools. A special place in the 
traumatic pathology of the brain is occupied by 
minor traumatic brain injuries that, although 
characterized by immediate mild signs and 
symptoms, can induce long-term brain pathology 
with increased disability potential. 
 Biomarkers of cerebral injuries may be a new 
diagnostic standard for traumatic brain injuries, and 
in particular, minor ones that often cannot be 
detected by cerebral CT. 
 However, further studies are needed to identify 
the biomarkers or combinations of biomarkers with 
the highest sensitivity and specificity for cerebral 
injuries. 
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